Download PDF
CC BY-NC-ND 4.0 · Asian J Neurosurg 2024; 19(01): 014-020
DOI: 10.1055/s-0042-1750783
Original Article

IDH1, ATRX, p53, and Ki67 Expression in Glioblastoma patients: Their Clinical and Prognostic Significance—A Prospective Study

Mukta Meel
1   Department of Pathology, SMS Medical College, Jaipur, Rajasthan, India
,
Arpita Jindal
1   Department of Pathology, SMS Medical College, Jaipur, Rajasthan, India
,
Mukesh Kumar
2   Department of Neurosurgery, SMS Medical College, Jaipur, Rajasthan, India
,
Kusum Mathur
1   Department of Pathology, SMS Medical College, Jaipur, Rajasthan, India
,
Ashok Singh
1   Department of Pathology, SMS Medical College, Jaipur, Rajasthan, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Context Glioblastoma multiforme (GBM) is a malignant and aggressive primary brain tumor with a poor prognosis. This adverse prognosis is due to the tumor's tendency for advancement and recurrence caused by highly intrusive nature of the persisting GBM cells that actively escape from the main tumor mass into the surrounding normal brain tissue. On the basis of biomarker illustration, it can be classified into molecular subgroups.

Aims (1) To determine the expression of IDH1, ATRX, p53, and Ki67 by immunohistochemistry, in a cohort of GBMs. (2) To determine whether altered protein expression of any of these growth-control genes in GBM will show association with patient survival. (3) To establish prognostically distinct molecular subgroups of GBM, irrespective of histopathological diagnosis.

Results In this prospective observational study, 35 histologically diagnosed cases of glioblastoma were enrolled. The mean age at the time of presentation was 43.46 ± 17.25 years with a male:female ratio of 1.3:1. Of the 35 cases, microvascular proliferation was seen in 23 cases. Large foci of necrosis (>50%) were seen in 10 cases and 27 cases had mitotic count ≥ 5/high power field (HPF). Of 35 cases, 5 (14.3%) cases showed IDH1 immunopositivity and 30 (85.7%) cases were negative for IDH1. ATRX was retained in 24 (68.6%) cases, while it was lost in 11 (31.4%) cases. The p53 immunoexpression was seen in 31 (88.6%) cases, whereas p53 was negative in 4 (11.4%) cases. The overall median survival (OS) was 6 months. In two protein pairs, the three compositions were IDH1–/p53+ (74.3%), ATRX +/IDH1– (62.9%), and ATRX +/p53+ (57.1%). Combined three-protein immunohistochemical analysis revealed five different molecular variants. Also, 8.6% (3/35) of the samples had aberrant protein expression of all three proteins, i.e., ATRX–/p53 +/IDH1 + , while 11.4% (4/35) were wild-type protein expression group, i.e., ATRX +/p53–/IDH1–.

Conclusion In patients with single protein expression, Kaplan–Meier survival analysis showed statistically better OS in IDH1 mutant glioblastomas. In cases with double protein pairs, IDH1/p53 revealed statistically significant association with better median OS. The survival analysis of patients with IDH1/ATRX/p53 protein combinations also denoted a better OS. Hence, GBM can be grouped into prognostically relevant subgroups using these protein expression signatures individually, as well as the combined protein expression signatures.

Keywords

ATRX - glioblastoma - IDH1 - overall survival

Ethical Approval

Ethical approval has been taken from institutional ethical committee.

All the authors have read and approved the manuscript.




Publication History

Article published online:
26 March 2024

© 2024. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Louis DN, Ohgaki H, Wiestler OD. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114 (02) 97-109
    CrossrefPubMedGoogle Scholar
  • 2 Ostrom QT, Gittleman H, Liao P. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-oncol 2014; 16 (Suppl. 04) iv1-iv63
    CrossrefPubMedGoogle Scholar
  • 3 Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15 (19) 6002-6007
    CrossrefPubMedGoogle Scholar
  • 4 Jiao Y, Killela PJ, Reitman ZJ. et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012; 3 (07) 709-722
    CrossrefPubMedGoogle Scholar
  • 5 Liu XY, Gerges N, Korshunov A. et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012; 124 (05) 615-625
    CrossrefPubMedGoogle Scholar
  • 6 Nguyen DN, Heaphy CM, de Wilde RF. et al. Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. Brain Pathol 2013; 23 (03) 237-243
    CrossrefPubMedGoogle Scholar
  • 7 Newcomb EW, Cohen H, Lee SR. et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 1998; 8 (04) 655-667
    CrossrefPubMedGoogle Scholar
  • 8 Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK. Glioblastoma. In: Kleihues P, Cavenee WK, eds. World Health Organization of Classification of Tumors: Pathology and Genetics of Tumors of the Nervous System. Lyon France: IARC; 2000: 29-39
    Google Scholar
  • 9 Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J. Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol 2003; 129 (08) 477-484
    CrossrefPubMedGoogle Scholar
  • 10 Lacroix M, Abi-Said D, Fourney DR. et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95 (02) 190-198
    CrossrefPubMedGoogle Scholar
  • 11 Laws ER, Parney IF, Huang W. et al; Glioma Outcomes Investigators. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003; 99 (03) 467-473
    CrossrefPubMedGoogle Scholar
  • 12 Song KS, Phi JH, Cho BK. et al. Long-term outcomes in children with glioblastoma. J Neurosurg Pediatr 2010; 6 (02) 145-149
    CrossrefPubMedGoogle Scholar
  • 13 Das KK, Mehrotra A, Nair AP. et al. Pediatric glioblastoma: clinico-radiological profile and factors affecting the outcome. Childs Nerv Syst 2012; 28 (12) 2055-2062
    CrossrefPubMedGoogle Scholar
  • 14 Suri V, Das P, Jain A. et al. Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro-oncol 2009; 11 (03) 274-280
    CrossrefPubMedGoogle Scholar
  • 15 Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry Kolluri VR. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Pediatr Neurosurg 2005; 41 (06) 292-299
    CrossrefPubMedGoogle Scholar
  • 16 Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 1987; 21 (02) 201-206
    CrossrefPubMedGoogle Scholar
  • 17 Simpson JR, Horton J, Scott C. et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993; 26 (02) 239-244
    CrossrefPubMedGoogle Scholar
  • 18 Kowalczuk A, Macdonald RL, Amidei C. et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 1997; 41 (05) 1028-1036 , discussion 1036–1038
    CrossrefPubMedGoogle Scholar
  • 19 Homma T, Fukushima T, Vaccarella S. et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 2006; 65 (09) 846-854
    CrossrefPubMedGoogle Scholar
  • 20 Pierallini A, Bonamini M, Pantano P. et al. Radiological assessment of necrosis in glioblastoma: variability and prognostic value. Neuroradiology 1998; 40 (03) 150-153
    CrossrefPubMedGoogle Scholar
  • 21 Nelson JS, Petito CK, Scott CB, Rotman A, Asbel S, Murry K. Glioblastoma with oligodendroglial features radiation (GBM-OL): Report from radiation therapy oncology group (RTOG) trial 8302. Lab Invest 1996; 74: 141A
    Google Scholar
  • 22 Hilton DA, Penney M, Pobereskin L, Sanders H, Love S. Histological indicators of prognosis in glioblastomas: retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival. Histopathology 2004; 44 (06) 555-560
    CrossrefPubMedGoogle Scholar
  • 23 Kraus JA, Lamszus K, Glesmann N. et al. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol 2001; 101 (04) 311-320
    CrossrefPubMedGoogle Scholar
  • 24 Pant I, Chaturvedi S, Suri V, Bansal AK, Jha DK, Gautam VK. Analysis of molecular markers in glioblastoma and correlation with survival pattern. Int J Clinicopathol Correl 2018; 2: 6-11
    Google Scholar